Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | ANPEP | P15144 | 1/20 | 0.35 |
| ▸ | PEPD | P12955 | 1/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.31 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.30 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14085831 | 1.00 | ATM (0.35) | ATMMMP2ANPEPPEPDABCB1 | |
| SCHEMBL9928395 | 0.83 | HCRTR2 (0.33) | ATMMMP2ANPEPABCB1SMN1; SMN2 | |
| SCHEMBL13071925 | 0.83 | HCRTR2 (0.33) | ATMMMP2ANPEPABCB1SMN1; SMN2 | |
| SCHEMBL11992649 | 0.82 | ATM (0.36) | ATMMMP2ANPEPPEPDABCB1 | |
| SCHEMBL20643679 | 0.82 | ATM (0.36) | ATMMMP2ANPEPPEPDABCB1 | |
| SCHEMBL10027153 | 0.82 | ATM (0.36) | ATMMMP2ANPEPPEPDABCB1 | |
| SCHEMBL13012273 | 0.82 | ATM (0.36) | ATMMMP2ANPEPPEPDABCB1 | |
| SCHEMBL24591630 | 0.81 | SMN1; SMN2 (0.38) | ATMMMP2ANPEPPEPDABCB1 | |
| SCHEMBL12227719 | 0.80 | SMN1; SMN2 (0.33) | PEPDSMN1; SMN2 | |
| SCHEMBL25557908 | 0.79 | JAK3 (0.32) | PEPD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022040-A1 | ANTIMICROBIALS | AMPLYX PHARMACEUTICALS, INC. | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022040-A1 | ANTIMICROBIALS | PAM, MPO, OXA1L | ATM 3232/4885MMP2 828/4885ANPEP 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.